Drug Trial Radar · NCT07179679
A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
Last checked: Nov 19, 2026Latest source record: Dec 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Dec 9, 2025
Primary completion
Oct 2027
Study completion Jun 2028
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TQB2934 is an anti-Cluster of Differentiation 3 (CD3) (Early T Cell Marker)×B cell maturation antigen (BCMA) double-specific antibody,and the isoform is IgG1(Native Immunoglobulin G1), which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA(B cell maturation antigen) to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells. TQB2934 for injection (subcutaneous injection) is intended for the treatment of patients with multiple myeloma.
Conditions
- Multiple Myeloma
Interventions
TQB2934 injection (subcutaneous injection)Drug
TQB2934 is an anti-CD3(Early T Cell Marker)×BCMA (B cell maturation antigen)double-specific antibody,and the isoform is Native Immunoglobulin G1 ( IgG1), which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA(B cell maturation antigen) to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Peak time (Tmax)Time frame: Within 120 hours after administration
- Peak drug concentration (Cmax)Time frame: Within 120 hours after administration
- Area under the plasma concentration-time curve (AUC0-last)Time frame: Within 120 hours after administration
- Elimination half-life (t1/2)Time frame: Within 120 hours after administration
- Apparent clearance (CL)Time frame: Within 120 hours after administration
- Adverse events(AEs)Time frame: Up to 24 months
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China · Not yet recruiting
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China · Not yet recruiting
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China · Not yet recruiting
The Affiliated Hospital of Chengde Medical College
Chengde, Hebei, China · Not yet recruiting
North China University of Science and Technology Affiliated Hospital
Tangshan, Hebei, China · Not yet recruiting
Nanjing Drum Tower hospital
Nanjing, Jiangsu, China · Recruiting
Jiangsu Province Hospital
Nanjing, Jiangsu, China · Not yet recruiting
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China · Not yet recruiting
Nanchang University First Affiliated Hospital
Nanchang, Jiangxi, China · Not yet recruiting
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China · Recruiting
Heze Municipal Hospital
Heze, Shandong, China · Not yet recruiting
Zhongshan Hospital of Fudan University
Shanghai, Shanghai Municipality, China · Not yet recruiting
Affiliated Hospital of North Sichuan Medical College
Nanchong, Sichuan, China · Not yet recruiting
Tianjin People's Hospital
Tianjin, Tianjin Municipality, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.